Lung cancer in women: Emerging differences in epidemiology, biology, and therapy

Chest

Volumn 128, Issue 1, 2005, Pages 370-381

  Thomas, Leno ^a   Doyle, L Austin ^a   Edelman, Martin J ^a,b  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

DNA repair; Estrogen receptor; Human papilloma virus; Non small cell lung cancer; Sex; Small cell lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIOXIDANT; CARCINOGEN; CISPLATIN; COTININE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GASTRIN RELEASING PEPTIDE RECEPTOR; GEFITINIB; GROWTH FACTOR RECEPTOR; NICOTINE; PROTEIN TYROSINE KINASE INHIBITOR; VIRUS DNA;

ADULT; ANTIOXIDANT ACTIVITY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CIGARETTE SMOKING; CONTROLLED STUDY; DIETARY INTAKE; DISEASE ASSOCIATION; DNA REPAIR; ENVIRONMENTAL EXPOSURE; FAMILY HISTORY; FEMALE; FRUIT; HORMONE SUBSTITUTION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IN SITU HYBRIDIZATION; LUNG ALVEOLUS CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; ONCOGENE K RAS; PASSIVE SMOKING; POLYMERASE CHAIN REACTION; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEX DIFFERENCE; SMOKING CESSATION; SOYBEAN; TOBACCO; TREATMENT OUTCOME; VEGETABLE; VIRUS DETECTION; VIRUS INFECTION; WART VIRUS;

EID: 22244472639     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.128.1.370     Document Type: Review

References (98)

1. Ahmedin JA, Tiwari RC, Murray T. Cancer statistics, 2004. CA Cancer J Clin 2004; 54:8-29
2. Patel JD, Bach PB, Kris MG. Lung cancer in US women: a contemporary epidemic. JAMA 2004; 291:1763-1768
3. United States Surgeon General. Reducing the health consequences: 25 years of progress. Washington, DC: US Government Printing Office, 1989
4. A report of the surgeon general: women and smoking. MMWR Morb Mortal Wkly Rep 2002. Available at: www.cdc. gov/mmwr. Accessed June 20, 2005
5. Zang EA, Wynder EL. Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst 1996; 88:183-192
6. Henschke CI, Miettinen OS. Women's susceptibility to tobacco carcinogens. Lung Cancer 2004; 43:1-5
7. Bain C, Feskanich D, Speizer F, et al. Lung cancer rates in men and women with comparable histories of smoking. J Natl Cancer Inst 2004; 96:826-834
8. Hackshaw AK, Law MR, Wald NJ. The accumulated evidence on lung cancer and environmental tobacco smoke. BMJ 1997; 315:980-988
9. Anderson KE, Carmella SG, Ye M, et al. Metabolites of a tobacco-specific lung carcinogen in nonsmoking women exposed to environmental tobacco smoke. J Natl Cancer Inst 2001; 93:378-381
10. Stockwell HG, Goldman AL, Lyman GH. Environmental tobacco smoke and lung cancer risk in nonsmoking women. J Natl Cancer Inst 1992; 84:1417-1422
11. Fontham ET, Correa P, Reynolds P, et al. Environmental tobacco smoke and lung cancer in nonsmoking women: a multicenter study. JAMA 1994; 271:1752-1759
12. Schwartz AG, Yang P, Swanson GM. Familial risk of lung cancer among nonsmokers and their relatives. Am J Epidemiol 1996; 144:554-562
13. Ooi WL, Elston RC, Chen VW, et al. Increased familial risk for lung cancer. J Natl Cancer Inst 1986; 76:217-222
14. Wu AH, Yu MC, Thomas DC, et al. Personal and family history of lung disease as risk factors for adenocarcinoma of the lung. Cancer Res 1988; 48:7279-7284
15. Tokuhata GK, Lilienfeld AM. Familial aggregation of lung cancer in humans. J Natl Cancer Inst 1963; 30:289-312
16. Mayne ST, Buenconsejo J, Janerich DT. Familial cancer history and lung cancer risk in United States nonsmoking men and women. Cancer Epidemiol Biomarkers Prev 1999; 8:1065-1069
17. Wu AH, Fontham ET, Reynolds P, et al. Family history of cancer and risk of lung cancer among lifetime nonsmoking women in the United States. Am J Epidemiol 1996; 143:535-542
18. Speizer FE, Colditz GA, Hunter DJ, et al. Prospective study of smoking, antioxidant intake and lung cancer in middle-aged women (USA). Cancer Causes Control 1999; 10:475-482
19. Michaud DS, Feskanich D, Rimm EB, et al. Intake of specific carotenoids and risk of lung cancer in 2 prospective US Cohorts. Am J Clin Nutr 2000; 72:990-997
20. Michaud DS, Feskanich D, Rimm ED, et al. Intake of specific caretinoids and risk of lung cancer in two prospective US cohorts. Am J Clin Nutr 2000; 72:990-997
21. Seow A, Poh WT, Teh M, et al. Diet, reproductive factors and lung cancer risk among Chinese women in Singapore: evidence for a protective effect of soy in nonsmokers. Int J Cancer; 2002; 97:365-371
22. Zhong L, Goldberg MS, Gao YT, et al. A population based case-control study of lung cancer and green tea consumption among women living in Shanghai China. Epidemiology 2001; 12:695-700
23. Henning EM, Suo Z, Karlsen F, et al. HPV positive bronchopulmonary carcinomas in women with previous high-grade cervical intraepithelial neoplasia (CIN III). Acta Oncol 1999; 38:639-647
24. Cheng Y-W, Chiou H-L, Sheu G-T, et al. The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women, Cancer Res 2001; 61:2799-2803
25. Yousem SA, Ohori, Sonmez-Alpan E. Occurrence of human papillomavirus DNA in primary lung neoplasms. Cancer 1992; 69:693-697
26. Hirayasu T, Iwamasa T, Kamada Y, et al. Human papillomavirus DNA in squamous cell carcinoma of the lung. J Clin Pathol 1996; 49:810-817
27. Tsuhako K, Nakazato I, Hirayasu T, et al. Human papillomavirus DNA in adenosquamous cell carcinoma of the lung. J Clin Pathol 1998; 51:741-749
28. Kaya H, Kotiloglu E, Inanli S, et al. Prevalence of human papillomavirus in laiyngeal and lung cancer. Pathologica 2001; 93:531-534
29. Gorgoulis VG, Zachartous P, Kotsinas A, et al. Human papillomavirus (HPV) is possibly involved in laryngeal but not in lung carcinogenesis. Hum Pathol 1999; 30:274-283
30. Welt A, Hummel M, Niedobitek G, et al. Human papillomavirus infection is not associated with bronchial carcinoma: evaluation by in situ hybridization and the polymerase chain reaction. J Pathol 1997; 181:276-280
31. Ryberg D, Hewer A, Phillips DH, et al. Different susceptibility to smoking-induced DNA damage among male and female lung cancer patients. Cancer Res 1994; 54:5801-5803
32. Mollerup S, Ryberg D, Hewer A, et al. Sex differences in lung CYP1A1 expression and DNA adduct levels among lung cancer patients. Cancer Res 1999; 59:3317-3320
33. Kawajiri K, NakachI K, Imai K, et al. The CYP1A1 gene and cancer susceptibility. Crit Rev Oncol Hematol; 1993; 14:77-87
34. Dresler CM, Fratelli C, Babb J, et al. Gender differences in genetic susceptibility for lung cancer. Lung Cancer 2000; 30:153-160
35. Seidegard J, Pero RW, Markowitz MM, et al. Isoenymes of glutathione transferase (class mu) as a marker for the susceptibility to lung cancer: a follow-up study. Carcinogenesis 1990; 11:33-36
36. Bennett WP, Alavanja MCR, Blomeke B, et al. Environmental tobacco smoke, genetic susceptibility and risk of lung cancer in non-smoking women. J Natl Cancer Inst 1999; 91:2009-2014
37. Kiyohara C, Otsu A, Shirakawa T, et al. Genetic polymorphisms and lung cancer susceptibility: a review. Lung Cancer 2003; 37:241-256
38. Mollerup S, Ryberg D, Hewer A. Sex differences in lung CYP1A1 expression and DNA adduct levels among lung cancer patients. Cancer Res 1999; 59:3317-3320
39. Rodenhuis S, Slebos RJ. The ras oncogene in human lung cancer. Am Rev Repir Dis 1990; 142:527-530
40. Nelson HH, Christiani DC, Mark EJ, et al. Implications and prognostic value of K-ras mutations for early-stage lung cancer in women. J Natl Cancer Inst (Bethesda) 1999; 91:2032-2038
41. Ahrendt SA, Decker PA, Aland EA, et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 2001; 92:1525-1530
42. Rodenhuis S, Slebos RJ. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 1992; 52(suppl):2665s-2669s
43. Graziano SL, Gamble GP, Newman NB, et al. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. J Clin Oncol 1999; 17:668-675
44. Rosell R, Li S, Skacel Z, et al. Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. Oncogene 1993; 8:2407-2412
45. Huncharek M, Muscat J, Geschwind JF. K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases: Carcinogenesis 1999; 20:1507-1510
46. Mitsudomi T, Steinberg SM, Oie HK, et al. Ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res 1991; 51:4999-5002
47. Nelson HH, Christiani DC, Mark EJ, et al. Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. J Natl Cancer Inst 1999; 91:2032-2038
48. Schiller JH, Adak S, Feins RH, et al. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy. J Clin Oncol 2001; 19:448-457
49. Greatens TM, Niehans GA, Rubins JB, et al. Do molecular markers predict survival in non-small-cell lung cancer? Am J Respir Crit Care Med 1998; 157:1093-1097
50. Schiller JH, Adak S, Feins R. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small cell lung cancer on E4592: a laboratory ancillary study on an Eastern Cooperative Oncology Group prospective randomized trial of postoperative adjuvant therapy. J Clin Oncol 2001; 19:448-457
51. Cuttitta F, Carney DN, Mulshine J, et al. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature 1985; 316:823-826
52. Leyton J, Garcia-Marin LJ, Tapia JA, et al. Bombesin and gastrin releasing peptide increase tyrosine phosphorylation of focal adhesion kinas and paxillin in non-small cell lung cancer cells. Cancer Lett 2001; 162:87-95
53. Shriver SP, Bourdeau HA, Gubish CT, et al. Sex-specific expression of gastrin-releasing peptide receptor: relationship to smoking history and risk of lung cancer. J Natl Cancer Inst (Bethesda) 2000; 92:24-33
54. Menard S. HER2 overexpression in various tumor types. Montreux, Switzerland: Proceedings of the HER-2 State-of-the-Art Conference, 1999; 10
55. Ardizzoni A, Cafferata MA, Paganuzzi M, et al. Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic an predictive factor in patients with advanced non-small cell lung carcinoma. Cancer 2001; 92:1896-1904
56. Rachwal WJ, Bongiorno PF, Orringer MB, et al. Expression and activation of erb-2 and epidermal growth factor receptor in lung adenocarcinomas. Br J Cancer 1995; 72:56-64
57. Hsieh CC, Chow KC, Fahn HJ, et al. Prognostic significance of HER-2/neu over expression in stage I adenocarcinoma of lung. Ann Thorac Surg 1998; 66:1159-1163
58. Hirsch F, Veve R, Varella-Garcia M. Evaluation of HER-2/neu expression in lung tumors by immunohistochemistry and fluorescence in situ hybridization [abstract]. Proc Am Soc Clin Oncol 2000; 19:486a
59. Gatzemeier U, Groth G, Butts C. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzamab in Her2-positive non-small cell lung cancer. Ann Oncol 2004; 15:19-27
60. Wei Q, Cheng L, Amos CI, et al. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiological study. J Natl Cancer Inst (Bethesda) 2000; 92:1764-1772
61. Spitz MR, Wei Q, Dong Q, et al. Genetic susceptibility to lung cancer: the role of DNA damage and repair. Cancer Epidemiol Biomarkers Prev 2003; 12:689-698
62. Lord RV, Brabender J, Gandara D. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002; 8:2286-2291
63. Mollerup S, Jorgensen K, Berge G, et al. Expression of estrogen receptors in human lung tissue and cell lines. Lung Cancer 2002; 37:153-159
64. Stabile LP, Davis G, Gubish CT, et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor α and β and show biological responses to estrogen. Cancer Res 2002; 62:2141-2150
65. Yager JD, Liehr JG. Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol 1996; 36:203-232
66. Fishman J. Biological action of catechol estrogens. J Endocrinol 1981; 85:59-65
67. Ignar-Trowbridge DM, Pimentel M, Parker MG, et al. Peptide growth factor cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinas C or estradiol. Endocrinology 1996; 137:1735-1744
68. Vargas SO, Leslie KO, Vacek PM, et al. Estrogen-receptor-related protein p29 in primary non small cell lung carcinoma. Cancer 1998; 82, 8:1495-1500
69. Yang MH. Estrogen receptor in female lung carcinoma [in Chinese with English abstract]. Chung Hua Chieh Ho Ho Hu His Tsa Chih 1992; 15:138-140,189
70. Adami HO, Persson I, Hoover R, et al. Risk of cancer in women receiving hormone replacement therapy. Int J Cancer 1989; 44:833-839
71. Taioli E, Wynder EL. Endocrine factors and adenocarcinoma of the lung in women. J Natl Cancer Inst (Bethesda) 1994; 86:869-870
72. Tham DM, Gardener CD, Haskell WL. Potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological and mechanistic evidence. J Clin Endocrinol Metab 1998; 83:2223-2235
73. Schabath MB, Wu X, Vassilopoulou-Sellin R, et al. Hormone replacement therapy and lung cancer risk: a case control analysis. Clin Cancer Res 2004; 10:113-123
74. Moore KA, Mery CM, Jaklitsch MT. Menopausal effects on presentation, treatment, and survival of women with non-small cell lung cancer. Ann Thorac Surg 2003; 76:1789-1795
75. Edmonson JH, Lagakos SW, Selawry OS. Cyclosphosphamide and CCNU in the treatment of inoperable small cell carcinoma and adenocarcinoma of the lung. Cancer Treat Rep 1976; 60:925-932
76. Ramalingam S, Pawlish K, Gadgeel S. Lung cancer in young patients: analysis of a Surveillance, Epidemiology, and End Results Database. Am J Clin Oncol 1998; 16:651-657
77. Radzikowska E, Glaz P, Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival: population-based study of 20,561 cases. Ann Oncol 2002; 13:1087-1093
78. Mitsudomi T, Tateishi M, Oka T, et al. Longer survival after resection of non-small cell lung cancer in Japanese women. Ann Thorac Surg 1989; 48:639-642
79. Minami H, Yoshimura M, Miyamoto Y, et al. Lung cancer in women: sex-associated differences in survival of patients undergoing resection for lung cancer. Chest 2000; 118:1603-1609
80. Ferguson MK, Wang J, Hoffman PC. Sex-associated differences in survival of patients undergoing resection for lung cancer. Ann Thorac Surg 2000; 69:245-250
81. Werner-Wasik M, Scott C, Cox JD, et al. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small cell lung cancer (LA-NSCLC): identification of five groups with different survival. Int J Radiat Oncol Biol Phys 2000; 48:1475-1482
82. Albain KS, Rusch VW, Crowley JJ. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995; 13:1880-1992
83. Albain KS, Crowley JJ, LeBlanc M, et al. Survival determinants in extensive-stage non-small cell lung cancer: the Southwest Oncology Group experience. Am J Clin Oncol 1991; 9:1618-1626
84. Paesmans M, Sculier JP, Libert G. Prognostic factors for survival in advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. J Clin Oncol 1995; 13:1221-1230
85. O'Connell J, Kris MG, Gralla RJ. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small cell lung cancer treated with combination therapy. J Clin Oncol 1986; 4:1604-1614
86. Keller SM, Vangel MG, Adak S, et al. The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer. Lung Cancer 2002; 37:030-309
87. Dannenberg K, Brabender J, Schneider S, et al. Gender differences in the predictive power of prognostic factors in NSCLC. Proc Am Soc Clin Oncol 2004; 22:619s
88. Johnson BE, Steinberg SM, Phelps R, et al. Female patients with small cell lung cancer liver longer than male patients. Am J Med 1988; 85:194-196
89. Paesmans M, Sculier JP, Lecomte J, et al. Prognostic factors for patients with small cell lung carcinoma. Cancer 2000; 89:523-533
90. Albain KS, Crowley JJ, LeBlanc M, et al. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group database. Am J Clin Oncol 1990; 8:1563-1574
91. Travis WD. Pathology of lung cancer. Clin Chest Med 2002; 23:65-81
92. Bhattacharjee A, Richards WG, Staunton J. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 2001; 98:13790-13705
93. Barkley JE, Green MR. Bronchiolalveolar carcinoma. J Clin Oncol 1996; 14:2377-2386
94. Fukuoka M, Yano S, Giaccone G. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21:2237-2246
95. Kris MG, Natale RB, Herbst RS. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290:2149-2158
96. Herbst RS, Giaccone G, Schiller J. Subset analysis of INTACT results for gefitinib (ZD1839) when combined with platinum based chemotherapy for advanced non-small cell lung cancer (abstract). Proc Am Soc Clin Oncol 2003; 22:627
97. Patel JD, Miller VA, Kris MG, et al. Encouraging activity and durable responses demonstrated by the epithelial growth factor receptor-tyrosine kinase inhibitor, erlotinib (Tarceva, OSI-774) in patients with advanced bronchiolalveolar cell carcinoma [abstract]. Lung Cancer 2003; 41(suppl):S56
98. Khuder SA, Mutgi AB. Effect of smoking cessation on major histologic types of lung cancer. Chest 2001; 120:1577-1583